vs
Side-by-side financial comparison of PennyMac Mortgage Investment Trust (PMT) and RHYTHM PHARMACEUTICALS, INC. (RYTM). Click either name above to swap in a different company.
PennyMac Mortgage Investment Trust is the larger business by last-quarter revenue ($93.6M vs $57.3M, roughly 1.6× RHYTHM PHARMACEUTICALS, INC.). PennyMac Mortgage Investment Trust runs the higher net margin — 56.0% vs -83.0%, a 138.9% gap on every dollar of revenue. On growth, RHYTHM PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (36.9% vs -13.3%). Over the past eight quarters, RHYTHM PHARMACEUTICALS, INC.'s revenue compounded faster (48.5% CAGR vs 12.3%).
PennyMac Mortgage Investment Trust is a U.S.-headquartered real estate investment trust specializing in residential mortgage assets. It invests in performing and non-performing mortgage loans, mortgage-backed securities, and credit risk transfer instruments, operating across investment management and mortgage servicing segments in the U.S. housing market.
Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.
PMT vs RYTM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $93.6M | $57.3M |
| Net Profit | $52.4M | $-47.5M |
| Gross Margin | — | 91.6% |
| Operating Margin | 38.6% | -82.2% |
| Net Margin | 56.0% | -83.0% |
| Revenue YoY | -13.3% | 36.9% |
| Net Profit YoY | 12.5% | -9.6% |
| EPS (diluted) | $0.49 | $-0.73 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $93.6M | $57.3M | ||
| Q3 25 | $99.2M | $51.3M | ||
| Q2 25 | $70.2M | $48.5M | ||
| Q1 25 | $44.5M | $32.7M | ||
| Q4 24 | $107.9M | $41.8M | ||
| Q3 24 | $80.9M | $33.3M | ||
| Q2 24 | $71.2M | $29.1M | ||
| Q1 24 | $74.2M | $26.0M |
| Q4 25 | $52.4M | $-47.5M | ||
| Q3 25 | $58.3M | $-52.9M | ||
| Q2 25 | $7.5M | $-46.6M | ||
| Q1 25 | $9.7M | $-49.5M | ||
| Q4 24 | $46.5M | $-43.3M | ||
| Q3 24 | $41.4M | $-43.6M | ||
| Q2 24 | $25.4M | $-32.3M | ||
| Q1 24 | $47.6M | $-141.4M |
| Q4 25 | — | 91.6% | ||
| Q3 25 | — | 89.3% | ||
| Q2 25 | — | 88.6% | ||
| Q1 25 | — | 88.8% | ||
| Q4 24 | — | 90.9% | ||
| Q3 24 | — | 88.5% | ||
| Q2 24 | — | 89.9% | ||
| Q1 24 | — | 89.2% |
| Q4 25 | 38.6% | -82.2% | ||
| Q3 25 | 47.4% | -102.6% | ||
| Q2 25 | 24.2% | -93.4% | ||
| Q1 25 | -14.2% | -143.7% | ||
| Q4 24 | 51.1% | -98.6% | ||
| Q3 24 | 32.8% | -132.0% | ||
| Q2 24 | 40.2% | -139.2% | ||
| Q1 24 | 43.6% | -538.7% |
| Q4 25 | 56.0% | -83.0% | ||
| Q3 25 | 58.7% | -103.1% | ||
| Q2 25 | 10.7% | -96.1% | ||
| Q1 25 | 21.8% | -151.4% | ||
| Q4 24 | 43.1% | -103.6% | ||
| Q3 24 | 51.2% | -131.2% | ||
| Q2 24 | 35.7% | -110.9% | ||
| Q1 24 | 64.2% | -544.4% |
| Q4 25 | $0.49 | $-0.73 | ||
| Q3 25 | $0.55 | $-0.82 | ||
| Q2 25 | $-0.04 | $-0.75 | ||
| Q1 25 | $-0.01 | $-0.81 | ||
| Q4 24 | $0.45 | $-0.71 | ||
| Q3 24 | $0.36 | $-0.73 | ||
| Q2 24 | $0.17 | $-0.55 | ||
| Q1 24 | $0.39 | $-2.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $190.5M | $388.9M |
| Total DebtLower is stronger | $1.1B | — |
| Stockholders' EquityBook value | $1.9B | $139.1M |
| Total Assets | $21.3B | $480.2M |
| Debt / EquityLower = less leverage | 0.58× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $190.5M | $388.9M | ||
| Q3 25 | $181.0M | $416.1M | ||
| Q2 25 | $108.6M | $291.0M | ||
| Q1 25 | $204.2M | $314.5M | ||
| Q4 24 | $103.2M | $320.6M | ||
| Q3 24 | $102.8M | $298.4M | ||
| Q2 24 | $336.3M | $319.1M | ||
| Q1 24 | $343.3M | $201.2M |
| Q4 25 | $1.1B | — | ||
| Q3 25 | $299.0M | — | ||
| Q2 25 | $1.2B | — | ||
| Q1 25 | $968.4M | — | ||
| Q4 24 | $1.0B | — | ||
| Q3 24 | $5.2B | — | ||
| Q2 24 | $5.4B | — | ||
| Q1 24 | $5.1B | — |
| Q4 25 | $1.9B | $139.1M | ||
| Q3 25 | $1.9B | $148.8M | ||
| Q2 25 | $1.9B | $-11.9M | ||
| Q1 25 | $1.9B | $18.9M | ||
| Q4 24 | $1.9B | $21.7M | ||
| Q3 24 | $1.9B | $11.2M | ||
| Q2 24 | $1.9B | $39.3M | ||
| Q1 24 | $2.0B | $61.6M |
| Q4 25 | $21.3B | $480.2M | ||
| Q3 25 | $18.5B | $506.9M | ||
| Q2 25 | $16.8B | $372.7M | ||
| Q1 25 | $14.9B | $386.7M | ||
| Q4 24 | $14.4B | $392.3M | ||
| Q3 24 | $13.1B | $363.6M | ||
| Q2 24 | $12.1B | $381.8M | ||
| Q1 24 | $12.3B | $258.7M |
| Q4 25 | 0.58× | — | ||
| Q3 25 | 0.16× | — | ||
| Q2 25 | 0.65× | — | ||
| Q1 25 | 0.51× | — | ||
| Q4 24 | 0.52× | — | ||
| Q3 24 | 2.70× | — | ||
| Q2 24 | 2.76× | — | ||
| Q1 24 | 2.60× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-7.2B | $-25.4M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | -137.76× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-7.2B | $-25.4M | ||
| Q3 25 | $-1.3B | $-26.6M | ||
| Q2 25 | $-2.0B | $-23.3M | ||
| Q1 25 | $-594.3M | $-40.4M | ||
| Q4 24 | $-2.7B | $-18.8M | ||
| Q3 24 | $-983.8M | $-25.2M | ||
| Q2 24 | $243.8M | $-29.1M | ||
| Q1 24 | $-342.4M | $-40.7M |
| Q4 25 | -137.76× | — | ||
| Q3 25 | -22.26× | — | ||
| Q2 25 | -267.53× | — | ||
| Q1 25 | -61.39× | — | ||
| Q4 24 | -58.08× | — | ||
| Q3 24 | -23.76× | — | ||
| Q2 24 | 9.59× | — | ||
| Q1 24 | -7.19× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PMT
| Other | $55.0M | 59% |
| Interest Rate Sensitive Strategies | $31.4M | 34% |
| Correspondent Production | $7.2M | 8% |
RYTM
Segment breakdown not available.
